Jeff Lagasse
Despite recent attention to rising pharmaceutical prices, a new study claims the total costs of treating patients with cancer in the United States have risen no faster than overall costs for Medicare and commercial insurance in the past decade.
Healthcare CEOs are increasingly focused on business-level issues, a new report by The Advisory Board has found, as consumerism continues to reshape the industry.
A majority of Americans, between 58 and 71 percent, don't see price and care as intricately linked, according to findings published in Health Affairs. However, a substantial minority, 21 to 24 percent, believe there is some correlation. Eight to 16 percent said they didn't know.
Theranos Inc., which offers cholesterol testing via skin-pricking, has acknowledged deficiencies in its Newark, California laboratory and says it has taken steps to address the issue.
A recent study of outcomes for common gastrointestinal problems finds that black people may fare better when treated at hospitals with more racially diverse populations.
A group of researchers has proposed a method for making expensive treatments for cancer, hepatitis C and other rare diseases more affordable: healthcare loans. They effectively work like a home mortgage and spread out payments for expensive treatments over time.
The Mayo Clinic's Florida campus will invest $100 million in major construction projects, with the first one slated to begin this summer. The world-renowned health organization will start the build on what it calls a "destination" medical building, providing integrated services for complex cancer, as well as neurologic and neurosurgical care.
The healthcare system in the United States is spending billions per year unnecessarily by continuing to use manual administrative processes for basic transactions, according to the 2015 CAQH Index released Wednesday.
A new analysis of data shows patients spend about $17 billion annually treating potentially avoidable complications of diabetes, said researchers at the Health Care Incentives Improvement Institute.
Cholesterol test results obtained through Theranos Inc. were substantially different than those from large laboratory companies, implying that doctors' medical decisions could be thrown off by Theranos-acquired results, a study finds.